Daniel Grizelj I believe that Vertex (NASDAQ:VRTX) stock is significantly undervalued because investors are massively underestimating the value of the company's pain treatment, VX-548. In my view, there's a good chance of VX-548 becoming a huge blockbuster. That's because I think there's a great hunger in America for a drug which treats pain more effectively than acetaminophen and NSAIDs and which patients are unlikely to abuse. And according to my calculations, Vertex's shares do not come close to reflecti ...